Generex Biotechnology Signs Letter of Intent to Acquire 51% in ALTuCELL, Inc. and their Cellular Therapy Product Altsulin® with Patented Microencapsulation Technology for the Treatment of Type I Diabetes Mellitis
(1)
(0)
Deliver breaking news, insightful commentary, and exclusive reports. Get in touch
benzingaheadline@gmail.com.
Target readers who trust our platform to stay ahead of the curve.